T1	Participants 101 125	hepatocellular carcinoma
T2	Participants 260 290	hepatocellular carcinoma (HCC)
T3	Participants 467 506	patients with curative resection of HCC
T4	Participants 744 800	21 patients received one dose and 19 received four doses
T5	Participants 1297 1307	two groups
